Showing 3851-3860 of 20452 results for "".
- Three-Year Longitudinal Findings of Tovorafenib in Pediatric Neuro-Oncology: Impact and Prospectshttps://reachmd.com/news/three-year-longitudinal-findings-of-tovorafenib-in-pediatric-neuro-oncology-impact-and-prospects/2484614/Day One Biosciences' three‑year follow‑up on tovorafenib (OJEMDA) repo
- ACR Convergence 2025: Rheumatoid Arthritis Clinical Trial Insightshttps://reachmd.com/news/acr-convergence-2025-rheumatoid-arthritis-clinical-trial-insights/2484603/The phase 1 trial Regulate-RA exploring SBT777101 described early signals of clini
- ACR 2025 SLE Treatment Guidelines: Key Organ-Specific Recommendations and Clinical Implicationshttps://reachmd.com/news/acr-2025-sle-treatment-guidelines-key-organ-specific-recommendations-and-clinical-implications/2484571/The ACR 2025 SLE guideline shifts care to organ-specific therapeutic pathways for systemic lupus erythematosus, prioritizi
- AI-Driven Precision: Enhancing Mental Health Diagnostics Through AI-Assisted Interviewshttps://reachmd.com/news/ai-driven-precision-enhancing-mental-health-diagnostics-through-ai-assisted-interviews/2484576/Alba AI conducted conversational assessments in 303 participants and showed higher concordance with confirmed psychiatric diagnoses than conventional rating sc
- Whooping Cough Surge Signals Urgent Call for Improved Surveillance and Vaccination Strategieshttps://reachmd.com/news/whooping-cough-surge-signals-urgent-call-for-improved-surveillance-and-vaccination-strategies/2484570/A nationwide resurgence of whooping cough is straining pathology and microbiology laboratories as vaccin
- Advancements in AMD Management: 5-Year Insights on Pegcetacoplan and Geographic Atrophyhttps://reachmd.com/news/advancements-in-amd-management-5-year-insights-on-pegcetacoplan-and-geographic-atrophy/2484581/Pegcetacoplan (Syfovre) given continuously for five years slows geographic atrophy (GA) pr
- Emerging Insights: Phase 3 Results of Telitacicept for IgA Nephropathyhttps://reachmd.com/news/emerging-insights-phase-3-results-of-telitacicept-for-iga-nephropathy/2484582/The telitacicept Phase 3 trial presented at ASN Kidney Week 2025 showed
- Understanding Glycemic Variability and Its Impact on Kidney Disease Progressionhttps://reachmd.com/news/understanding-glycemic-variability-and-its-impact-on-kidney-disease-progression/2484561/Continuous glucose monitoring data from a matched cohort link distinct glucotypes and visceral adiposity profiles to faster kidney‑disease progressio
- Real-World Safety of MS Therapies: Insights from the Austrian MS Treatment Registryhttps://reachmd.com/news/real-world-safety-multiple-sclerosis-therapies-austrian-registry/2484536/Registry data from the Austrian MS Treatment Registry show that real-world adverse event (AE) patterns across disease-modifying therapies (DMTs) largely mirror clinical trial
- Behavioral Impact of Ultra-Processed Foods on Young Adultshttps://reachmd.com/news/behavioral-impact-ultra-processed-foods-young-adults/2484526/A Virginia Tech study found that exposure to ultra-processed diets made 18-21-year-olds consume more calories, even when not hungry. In a tightly controlled crossover feeding